ArticleBMJ global health2025
The impact of the COVID-19 pandemic on HIV, malaria, tuberculosis and childhood vaccination services in Guinea: an interrupted time series analysis.
Article in BMJ global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEvidence impact of the COVID-19 pandemic on health-related indicator in Sub-Saharan Africa is limited. We aimed to assess the indirect effect of COVID-19 on essential health service and outcomes in Guinea.
methodsIn this interrupted time series analysis, we analysed a nationally surveillance data from January 2018 to December 2022 of nine indicators of HIV, malaria, tuberculosis (TB) and childhood vaccination. We fitted a Poisson segmented regression model accounting for seasonality to estimate the immediate impact of the COVID-19 on these outcomes as well as per-pandemic trend through incidence rate ratio (IRRs) with 95% CIs.
resultsBetween January 2018 and December 2022, the month-to-month (quarter-to-quarter for TB) changes before COVID-19 outbreak increased from 0.4% to 6.4% in all indicators except for TB therapeutic success rate (IRR 0.995, 95% CI 0.987 to 1.004). Overall, there was a decrease in three indicators ranging from 6% for pentavalent vaccine (IRR 0.940, 0.906 to 0.974) to 15% for TB total cases notification (IRR 0.850, 0.785 to 0.920). The pandemic COVID-19 trend significantly downward monthly for four indicators ranging from 0.8% for in-patient malaria cases (IRR 0.992, 0.986 to 0.998) to 8% for PCR test in infants (IRR 0.920, 0.902 to 0.938), and significantly increased monthly by 2.5% for TB-positive microscopy (IRR 1.025, 1.015 to 1.036) and by 0.9% for TB therapeutic success rate (IRR 1.009, 1.001 to 1.017).
conclusionIn Guinea, during the 2020 COVID-19 pandemic, the malaria indicators were generally maintained, while the number of HIV tests in infants, childhood vaccines and TB indicators were heavily impacted. There is an urgent need for more protective and targeted strategies to improve the preparedness of the healthcare service.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.